The Onco'Zine Brief

26/09/2026

Meet Proveo at CPHI Milan 2026 🇮🇹

Proveo™, a Cerbios-Pharma brand and part of HAS Group, will be at CPHI Milan, October 6–8, 2026 — and we'd like to meet you there.

We bring together deep expertise in bioconjugation and cytotoxic linker-payloads, backed by an integrated network for recombinant protein production, aseptic fill-finish, and lyophilization — supporting your ADC program from early development through commercial manufacturing.

📍 Find us at the HAS Group Booth — Stand

Whether you're advancing an early-stage ADC program, preparing for clinical development, or evaluating manufacturing partners, our team would welcome the opportunity to discuss your requirements.

👉 Schedule a meeting with us: https://conta.cc/4xQvThf
👉 Read Our Newsletter https://conta.cc/4hmcQ8q

Meet Proveo at CPHI Milan 2026 Meet the Proveo™ team at CPHI Milan 2026, October 6–8 — schedule a meeting to discuss your ADC program. PART OF ADC INTEGRATED DEVELOPMENT AND MANUFACTURING HAS Group Bo

18/06/2026

https://conta.cc/4eunZ5Q

Early‑stage development of antibody–drug conjugates (ADCs) and other bioconjugates depends on making the right decisions—fast. From conjugation conditions to analytical strategy, early insight can significantly influence downstream manufacturability and risk.

24/05/2026

As the 2026 annual meeting of the American Society for Clinical Oncology (ASCO) approaches, our specialized oncology-focused team is gearing up to deliver comprehensive coverage from Chicago, Illinois. With more than 3,400 abstracts and late-breaking clinical trials, ASCO remains the world’s premi...

31/03/2026

https://conta.cc/40zeStP

Email from Sunvalley Communication, LLC   March Newsletter   March 31, 2026 | 06   Diagnosing Colorectal Cancer: Debunking 5 Persistent Myths Many young adults mistakenly believe colorectal cancer is

20/01/2026

https://conta.cc/4qvklNT

Email from Sunvalley Communication, LLC Europe’s definitive ADC event!     Greetings! Is the 16th World ADC London on your radar? Next month, 800+ ADC leaders from Europe, North America, and Asia will

19/11/2025

https://conta.cc/4piJ7iX

Antibody-drug conjugates (ADCs) are transforming therapeutic strategies—but their analytical development is anything but straightforward. Unlike small molecules or biologics, ADCs combine two modalities, creating unique challenges for scientists and developers.

11/06/2025

Join us at the London Biotechnology Show 2025, where innovation meets opportunity! https://conta.cc/3HB1cZ0

Dear Reader, Join us at the London Biotechnology Show 2025, where innovation meets opportunity! Whether you are looking to explore the latest biotech breakthroughs with a complimentary Visitor Pass or gain premium access to industry leaders and exclusive content with a Delegate Pass, we have got the...

13/05/2025

Discover the latest advancements in cancer research from AACR 2025! held in Chicago, Illinois, April 25 - 30. ,
https://conta.cc/4mx84qH

Email from Sunvalley Communication, LLC You don't want to miss this.   Conference Coverage   May 13, 2025 | 05   Highlights from the Annual Meeting of the American Association for Cancer Research (AAC

20/03/2024

Listen to the latest episodes of The Onco'Zine Brief

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland and covers a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. The Onco'Zine Brief is a sponsor-supported, program for healthcar...

25/01/2024

From the Oncology Nursing Forum editor: “We are expanding our focus and outreach.” ONF readers can look forward to a themed issue focusing on areas of oncology nursing symptom science. Read more about what to expect from ONF in 2024 in January’s Editorial. https://bit.ly/3U56T5V